ATE530167T1 - COMBINED DOSAGE FORM CONTAINING A CHOLESTEROL LOWERING AGENT, A RENIN-ANGIOTENSIN INHIBITOR AND ACETYL SALICYLIC ACID - Google Patents

COMBINED DOSAGE FORM CONTAINING A CHOLESTEROL LOWERING AGENT, A RENIN-ANGIOTENSIN INHIBITOR AND ACETYL SALICYLIC ACID

Info

Publication number
ATE530167T1
ATE530167T1 AT02773266T AT02773266T ATE530167T1 AT E530167 T1 ATE530167 T1 AT E530167T1 AT 02773266 T AT02773266 T AT 02773266T AT 02773266 T AT02773266 T AT 02773266T AT E530167 T1 ATE530167 T1 AT E530167T1
Authority
AT
Austria
Prior art keywords
active agents
renin
dosage form
lowering agent
salicylic acid
Prior art date
Application number
AT02773266T
Other languages
German (de)
Inventor
Shubha Chungi
Theodore Iorio
Original Assignee
Brigham & Womens Hospital
Massachusetts College Of Pharmacy And Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25477337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE530167(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital, Massachusetts College Of Pharmacy And Health Sciences filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE530167T1 publication Critical patent/ATE530167T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally at least one of vitamin B6, B12, and folate; the active agents are each present in a unit dose appropriate for once-daily dosing, and at least one of the active agents is contained in a dosage unit within the dosage form that physically separates it from the other active agents. The formulation is provided as a simple and convenient therapy to reduce the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The formulation is also therapeutic for individuals during or immediately following an occurrence of acute myocardial infarction.
AT02773266T 2001-08-28 2002-08-28 COMBINED DOSAGE FORM CONTAINING A CHOLESTEROL LOWERING AGENT, A RENIN-ANGIOTENSIN INHIBITOR AND ACETYL SALICYLIC ACID ATE530167T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/941,948 US6669955B2 (en) 2001-08-28 2001-08-28 Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
PCT/US2002/027877 WO2003020243A1 (en) 2001-08-28 2002-08-28 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin

Publications (1)

Publication Number Publication Date
ATE530167T1 true ATE530167T1 (en) 2011-11-15

Family

ID=25477337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773266T ATE530167T1 (en) 2001-08-28 2002-08-28 COMBINED DOSAGE FORM CONTAINING A CHOLESTEROL LOWERING AGENT, A RENIN-ANGIOTENSIN INHIBITOR AND ACETYL SALICYLIC ACID

Country Status (13)

Country Link
US (1) US6669955B2 (en)
EP (1) EP1429729B1 (en)
JP (3) JP2005504064A (en)
KR (1) KR20040037075A (en)
CN (2) CN1575162A (en)
AT (1) ATE530167T1 (en)
AU (1) AU2002336419B2 (en)
CA (1) CA2461958C (en)
ES (1) ES2307463T3 (en)
IL (2) IL160643A0 (en)
NZ (1) NZ532014A (en)
WO (1) WO2003020243A1 (en)
ZA (1) ZA200402417B (en)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423055B1 (en) * 1999-07-14 2002-07-23 Cardiofocus, Inc. Phototherapeutic wave guide apparatus
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2005508358A (en) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド Method of treatment using gastric retention type losartan dosage
MXPA04009968A (en) 2002-04-09 2004-12-13 Flamel Tech Sa Oral suspension of active principle microcapsules.
EP1501546B1 (en) * 2002-05-03 2012-10-10 Hexal AG Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
US20050182106A1 (en) * 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
CN100341509C (en) * 2002-07-11 2007-10-10 三共株式会社 Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
CA2530788C (en) * 2003-06-26 2010-02-09 Teva Pharmaceutical Industries Ltd Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
NZ544784A (en) * 2003-07-28 2009-11-27 Reddys Lab Inc Dr Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd Composition and method for treatment and prevention of atherosclerosis
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
CA2572815A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US20060034913A1 (en) * 2004-08-13 2006-02-16 James Gaede Multiplex drug delivery device
CN104958270A (en) * 2004-08-25 2015-10-07 伊森舍丽斯有限公司 Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
CA2581816A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
WO2006084560A1 (en) * 2005-02-09 2006-08-17 Unilever N.V. Composition comprising peptide
EP1865972B1 (en) * 2005-03-23 2013-11-06 CHS Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
JP2008535928A (en) * 2005-04-12 2008-09-04 シヴィダ・インコーポレイテッド HMGCoA reductase inhibitor combinations and uses thereof
US20060292225A1 (en) * 2005-06-24 2006-12-28 Felix Arthur M Water soluble analgesic formulations and methods for production
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
CN1903364B (en) * 2005-07-26 2011-06-22 安徽省现代中药研究中心 Pharmaceutical composition containing angiotensin converting enzyme inhibitor and phenoxy acid compound
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
WO2007053406A1 (en) * 2005-10-28 2007-05-10 Novartis Ag Combinations of antihypertensive and cholesterol lowering agents
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007068287A1 (en) * 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
WO2007091253A2 (en) * 2006-02-06 2007-08-16 C.T.S. Ltd. Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels
EP1818050A1 (en) * 2006-02-10 2007-08-15 Stada Arzneimittel Ag Stable pharmaceutical compositions comprising a HMG-CoA reductase inhibitor
EP1825848A3 (en) * 2006-02-10 2010-03-03 Stada Arzneimittel Ag Stable pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
US20070196515A1 (en) * 2006-02-22 2007-08-23 Kothari Shil C Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome X
EP2010162A4 (en) * 2006-04-03 2013-01-09 Isa Odidi Drug delivery composition
WO2007121356A2 (en) * 2006-04-13 2007-10-25 Accu-Break Technologies Method of treatment with predictably breakable pharmaceutical tablets
WO2007120930A2 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
ES2300188B1 (en) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. BICAPA COMPRESSED FOR THE PREVENTION OF CARDIOVASCULAR ACCIDENTS.
CA2654529A1 (en) * 2006-07-06 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions with controlled pharmacokinetics
US20080026053A1 (en) * 2006-07-28 2008-01-31 Sovereign Pharmaceuticals, Ltd. Capsule containing granular pharmaceutical compositions
CN101534798B (en) * 2006-10-30 2012-02-15 韩诺生物制约株式会社 Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
US8642083B2 (en) 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
KR100870396B1 (en) * 2006-12-07 2008-11-25 보령제약 주식회사 Oral administrative dosage form for treating cardiovascular system disease
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
JP5467870B2 (en) * 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド Dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2008109462A2 (en) * 2007-03-02 2008-09-12 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
ES2963291T3 (en) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Manufacturing of multiple mini capsules
WO2009022821A2 (en) * 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
SI2200588T1 (en) 2007-09-25 2019-08-30 Solubest Ltd. Compositions comprising lipophilic active compounds and process for their preparation
WO2009045795A2 (en) * 2007-09-28 2009-04-09 Novartis Ag Galenical formulations of aliskiren and valsartan
EP2070520A1 (en) * 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
MX344778B (en) * 2008-01-25 2017-01-06 Duo-Ge COMBINATION OF ORAL MEDICINES UNITED BY A WRAP.
CN101980701A (en) * 2008-03-28 2011-02-23 菲尔若国际公司 Capsule for the prevention of cardiovascular diseases
CN102088965B (en) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 Application of salicylate (ester) conjugates in the preparation of medicines for treating metabolic disorders
CN101590240B (en) * 2008-05-30 2012-04-25 北京奥萨医药研究中心有限公司 Composition containing angiotensin II receptor antagonist, statin and folic acid and application
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
US9789187B2 (en) * 2009-02-11 2017-10-17 Cadila Pharmaceuticals Limited Stable pharmaceutical composition for atherosclerosis
JP2012520342A (en) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN102421424A (en) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 Combination therapies for treating metabolic disorders
ES2530049T3 (en) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composition comprising drops of oil
US20120064161A1 (en) * 2009-05-18 2012-03-15 Dr. Reddy's Laboratories, Inc. Modified release niacin pharmaceutical formulations
BR112012002963A2 (en) 2009-08-12 2017-10-24 Sigmoid Pharma Ltd immunomodulatory compositions comprising a polymer matrix and an oil phase
JP5827952B2 (en) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． Pharmaceutical composition having both rapid action and durability
JP4899224B2 (en) * 2010-05-11 2012-03-21 春三 小林 Arteriosclerosis improving agent
TR201005325A2 (en) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Pharmaceutical formulations containing atorvastatin and aspirin
WO2012028966A2 (en) * 2010-07-21 2012-03-08 Nucitec S.A. De C.V. Combination dosage compositions comprising a cholesterol-lowering agent, a renin-angiotensin system inhibitor, an antioxidant agent and an antiplatelet agent for treatment and prevention of cardiovascular disease
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP6106359B2 (en) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 Solid formulation containing loxoprofen sodium and vitamin B1
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
ES2755075T3 (en) * 2011-05-05 2020-04-21 Hennig Arzneimittel Gmbh&Co Kg Pharmacological form for the targeted release of active ingredients
KR101840086B1 (en) * 2011-07-15 2018-03-19 액세스 비지니스 그룹 인터내셔날 엘엘씨 Multicarotenoid beadlets and related method
EP3167876B1 (en) * 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
JP6160263B2 (en) * 2012-06-07 2017-07-12 大正製薬株式会社 Loxoprofen-containing pharmaceutical composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
ES2524645B1 (en) * 2013-06-06 2015-12-02 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
DK3021832T3 (en) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh PRESERVED ETHERIFIED CYCLODEXTRINE DERIVATIVES CONTAINING LIQUID AQUATIC PHARMACEUTICAL COMPOSITION
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
ES2593210T3 (en) 2013-12-04 2016-12-07 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
CN104001176B (en) * 2014-06-11 2016-06-22 深圳奥萨医药有限公司 The pharmaceutical composition of platelet ADP receptor antagonist and vitamin B group
EA036036B1 (en) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Compositions comprising cyclosporin
JP6709226B2 (en) 2014-11-14 2020-06-10 エッセンシャライズ インコーポレイテッド Method for treating a subject having Prader-Willi syndrome or Smith-Magenis syndrome
GB2533669B (en) * 2014-12-23 2016-12-14 Innovate Pharmaceuticals Ltd Salicylate compound composition
BE1023011B1 (en) * 2015-08-05 2016-11-04 Nordic Specialty Pharma Bvba Acetylsalicylic acid tablet with immediate release
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018124236A1 (en) * 2016-12-27 2018-07-05 国立大学法人大阪大学 Medicinal composition for treating intractable heart disease
WO2019109415A1 (en) * 2017-12-04 2019-06-13 清华大学 Compound for targeted degradation of hmgcr and application thereof
MX2021012728A (en) 2019-04-17 2022-01-24 Cardiopharma Inc Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture.
KR20240029726A (en) * 2021-07-23 2024-03-06 프로캡스 에스에이 Soft shell gelatin capsules

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5157025A (en) 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
EP0622078B1 (en) 1992-01-14 1999-09-01 Hisamitsu Pharmaceutical Co., Inc. Cholesterol level depressant
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6251852B1 (en) * 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
HUP0203326A3 (en) 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
ATE326240T2 (en) 2000-04-10 2006-06-15 Nicholas John Wald COMPOSITION FOR THE PREVENTION OF CARDIOVASCULAR DISEASES
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
EP1429729A4 (en) 2007-07-04
US20030068366A1 (en) 2003-04-10
JP2005504064A (en) 2005-02-10
US6669955B2 (en) 2003-12-30
ES2307463T1 (en) 2008-12-01
WO2003020243A1 (en) 2003-03-13
NZ532014A (en) 2005-12-23
IL160643A (en) 2010-02-17
CN1575162A (en) 2005-02-02
EP1429729B1 (en) 2011-10-26
AU2002336419B2 (en) 2007-07-19
CN101642459A (en) 2010-02-10
ES2307463T3 (en) 2012-03-12
CA2461958A1 (en) 2003-03-13
IL160643A0 (en) 2004-07-25
EP1429729A1 (en) 2004-06-23
CA2461958C (en) 2010-05-11
JP2009256381A (en) 2009-11-05
KR20040037075A (en) 2004-05-04
ZA200402417B (en) 2005-06-29
JP2013006857A (en) 2013-01-10

Similar Documents

Publication Publication Date Title
IL160643A0 (en) Combination dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor, and aspirin
Black et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
EE200200086A (en) Use of a renin-angiotensin system inhibitor, a combined product, and a method for preventing cardiovascular events
BRPI0412557A (en) pharmaceutical dosage form of cardiovascular events
ATE356612T1 (en) ORAL PHARMACEUTICAL DOSAGE FORMS OF LIQUID MEDICATIONS WITH IMPROVED BIOAVAILABILITY
WO2003039519A3 (en) Dual controlled release dosage form
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
DK1239857T3 (en) Dual-release preparations of a cyclooxygenase-2 inhibitor
ATE509616T1 (en) TOPICAL PHARMACEUTICAL AND/OR COSMETIC DOSAGE SYSTEMS
NO962841D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives such as colon cancer chemopreventives and chemotherapeutic agents
IL166761A (en) Use of cgrp antagonist compounds for the manufacture of medicaments for treating psoriasis
TR199800631A2 (en) Pharmaceutical formulation.
Roenigk Jr Acitretin combination therapy
FR2878161B1 (en) ORAL MEDICINE FORM, SOLID AND DESIGNED TO AVOID MEASUREMENT
ATE247953T1 (en) DELAYED-RELEASE MEDICINAL PRODUCTS CONTAINING ISOQUERCETIN AND ASCORBIC ACID
FR2878158B1 (en) ORAL PHARMACEUTICAL FORM, SOLID MICROPARTICULAR DESIGNED TO PREVENT MEASUREMENT
WO2004056320A3 (en) Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
Marrs Spironolactone management of resistant hypertension
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
PT1656131E (en) Use of betaine for treating intermittent claudication
CA2385755A1 (en) Prevention of colorectal cancer
CA2394471A1 (en) External preparation for treating pruritus
DK1492539T3 (en) Statin therapy to enhance cognitive function
BG108144A (en) New use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties